Lympho-epithelial Kazal-type inhibitor (LEKTI) is a serine protease inhibitor which protects mucous epithelia against microbial attack and inflammation. LEKTI is a marker of epithelial differentiation and expresses strongly in the granular and uppermost spinous layers of the epidermis and differentiated layers of stratified epithelia. Defects in SPINK5, the gene encoding LEKTI, are the cause of Netherton syndrome, a severe autosomal recessive disorder characterized by atopic dermatitis, hayfever and other conditions.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Protein Aliases: Hemofiltrate peptide HF6478; Hemofiltrate peptide HF7665; ISK5; LEKTI; Lympho-epithelial Kazal-type-related inhibitor; Lymphoepithelial Kazal type related inhibitor; lymphoepithelial Kazal-type-related inhibitor; Netherton syndrome; NETS; NS; Serine peptidase inhibitor Kazal type 5; Serine protease inhibitor Kazal-type 5; serine protease inhibitor, Kazal type 5; SPINK5; VAKTI
Gene Aliases: 2310065D10Rik; AV238912; LEKT1; LEKTI; LETK1; LETKI; NETS; NS; SPINK5; VAKT1; VAKTI
UniProt ID: (Human) Q9NQ38
Molecular Function: enzyme modulator